




FIG. 1

CD8 α 1	1	MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNFTSGCSWLFQP	60
		MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNFTSGCSWLFQP	
m1CD8 α	1	MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNFTSGCSWLFQP	60
CD8 α 1	61	RGAAASPTFLLYLSQNKPKAAEGLDTQRFSGKRLGDTFVLTLSDFRRENEGYYFCSALSN	120
		RGAAASPTFLLYLSQNKPKAAEGLDTQRFSGKRLGDTFVLTLSDFRRENEGYYFCSALSN	
m1CD8 α	61	RGAAASPTFLLYLSQNKPKAAEGLDTQRFSGKRLGDTFVLTLSDFRRENEGYYFCSALSN	120
CD8 α 1	121	SIMYFSHFVPVFLPAKPTT-TPAPRPFTPAPTIASQPLSL-RPEACRPAAGGAVHTRGLD	178
		SIMYFSHFVPVFLPA P PT T+ + L RPE T+	
m1CD8 α	121	SIMYFSHFVPVFLPASVVDLPTTAQPTKKSTLKKRVCRLEPPE-----TQKGP	169
CD8 α 1	179	FACDEYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKS GDKPSLSARYV	235
		YIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKS GDKPSLSARYV	
m1CD8 α	179	LCSEYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKS GDKPSLSARYV	226

FIG. 2

CD8 α 2	1	MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNFTSGCSWLFQP	60
m2CD8 α	1	MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNFTSGCSWLFQP	60
CD8 α 2	61	RGAAASPTFLLYLSQNKPKAAEGLDTQRFSGKRLGDTFVLTLSDFRRENEG C YFCSALSN	120
m2CD8 α	61	RGAAASPTFLLYLSQNKPKAAEGLDTQRFSGKRLGDTFVLTLSDFRRENEG C YFCSALSN	120
CD8 α 2	121	SIMYFSHFVPVFLPA KPTT-TPAPRPFTPAPTIASQPLSL-RPEACRPAAGGAVHTRGLD	178
m2CD8 α	121	SIMYFSHFVPVFLPA PPTT+L RPE	169
CD8 α 2	179	FACD E YIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKS GDKPSLSARYV	235
m2CD8 α	179	LCSE E YIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKS GDKPSLSARYV	226

FIG. 3




FIG. 4




FIG. 5A




FIG. 5B



FIG. 6





FIG. 7A

**FIG. 7B**




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16






FIG. 17

**FIG. 18**




FIG. 19

D150081 PBMCs/JUACC257
(TCR+ normalized E/T 4:1)




FIG. 20A




FIG. 20B

D150081 PBMCs/MCF7
(TCR+ normalized E/T 4:1)




FIG. 20C

UACC257
(E: T::4:1)




FIG. 21A

A375
E: T::4:1




FIG. 21B




FIG. 22




FIG. 23A




FIG. 23B




FIG. 24A




FIG. 24B




FIG. 25A




FIG. 25B




FIG. 26




FIG. 27A




FIG. 27B





FIG. 28

**FIG. 29A**




FIG. 29B




FIG. 30A




FIG. 30B




FIG. 31A






FIG. 31B

**FIG. 32A**

**FIG. 32B**





FIG. 33A

**FIG. 33B**




FIG. 34A






FIG. 34B

**FIG. 35A**

**FIG. 35B**




FIG. 36A




FIG. 36B




FIG. 37




FIG. 38




FIG. 39




FIG. 40




FIG. 41




FIG. 42




FIG. 43




FIG. 44A




FIG. 44B




FIG. 45A

Tumor Growth Index
(Integrated AUC; normalized to tumor_{only} condition)




FIG. 45B




FIG. 46






FIG. 47

**FIG. 48A****FIG. 48B**




FIG. 48C











FIG. 48D

**FIG. 48E****FIG. 48F**

**FIG. 48G**

**FIG. 49A****FIG. 49B**

**FIG. 49C****FIG. 49D**




FIG. 49E












FIG. 49F

**FIG. 49G**

**FIG. 50A****FIG. 50B**

**FIG. 50C****FIG. 50D**

**FIG. 50E****FIG. 50F**

**FIG. 50G**

Gated on CD4+CD8+




FIG. 51A




FIG. 51B




FIG. 51C

Gated on CD4-CD8+




FIG. 52A




FIG. 52B




FIG. 52C

Gated on CD3+TCR+




FIG. 53A




FIG. 53B




FIG. 53C




FIG. 54





FIG. 55A

FIG. 55B

FIG. 55C






FIG. 57




FIG. 58




FIG. 59




FIG. 60




FIG. 61




FIG. 62




FIG. 63A




FIG. 63B





FIG. 63C


CD4+ selected	CD8 α ^{hi} TCR		CD8 α ^{lo} TCR		TCR	
Donor #1	0.51		10.6		-	
Donor #2	0.43		4.0		-	
Donor #3	1.21		60.0		-	

FIG. 63D




	#10	TCR
EC50 (ng/ml)	0.246	0.276
%CD3+tet+	42.2	17.1

FIG. 64A



	#10	TCR
EC50 (ng/ml)	0.360	0.591
%CD3+tet+	54.7	24.2

FIG. 64B



	#10	TCR
EC50 (ng/ml)	0.608	1.549
%CD3+tet+	45.5	16.6

FIG. 64C

Summary EC50_PBMC product Un-normalized E:T::1:1






FIG. 64D




	#10	TCR
EC50 (ng/ml)	0.116	0.295

FIG. 65A



	#10	TCR
EC50 (ng/ml)	0.166	0.153

FIG. 65B



	#10	TCR
EC50 (ng/ml)	0.51	-

FIG. 65C